Recce Pharmaceuticals (ASX:RCE) LT-Debt-to-Total-Asset : 0.13 (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Recce Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.13.

Recce Pharmaceuticals's long-term debt to total assets ratio increased from Dec. 2023 (0.01) to Dec. 2024 (0.13). It may suggest that Recce Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Recce Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Recce Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals LT-Debt-to-Total-Asset Chart

Recce Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.09

Recce Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial													0.03	0.04	0.01	0.09	0.13

Recce Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Recce Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )	/	Total Assets (A: Jun. 2024 )
	=	0.587	/	6.616
	=

Recce Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0.533	/	4.207
	=

Recce Pharmaceuticals (ASX:RCE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Recce Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Recce Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

R9Q:Germany

Address

180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000

Website

https://www.recce.com.au

Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.

Recce Pharmaceuticals Headlines

No Headlines